<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    10990583
   </pmid>
   <datecreated>
    <year>
     2000
    </year>
    <month>
     10
    </month>
    <day>
     02
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2000
    </year>
    <month>
     10
    </month>
    <day>
     02
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     19
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0736-8046
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       17
      </volume>
      <issue>
       4
      </issue>
      <pubdate>
       <medlinedate>
        2000 Jul-Aug
       </medlinedate>
      </pubdate>
     </journalissue>
     <title>
      Pediatric dermatology
     </title>
     <isoabbreviation>
      Pediatr Dermatol
     </isoabbreviation>
    </journal>
    <articletitle>
     Oral griseofulvin remains the treatment of choice for tinea capitis in children.
    </articletitle>
    <pagination>
     <medlinepgn>
      304-9
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      Tinea capitis is one of the most common infections of children. The standard treatment is griseofulvin. Itraconazole and terbinafine have in large part replaced griseofulvin in the treatment of onychomycosis and, in addition to fluconazole and ketoconazole, are evolving treatments for tinea capitis. The purpose of this review is to compare the efficacy, safety, and cost of oral antifungal agents for tinea capitis. Small, open-label studies of itraconazole, terbinafine, and fluconazole have reported encouraging results, suggesting that these drugs may be effective alternatives to griseofulvin; however, in large controlled studies griseofulvin continues to exhibit greater or equal efficacy. Ketoconazole appears to be the least efficacious. All five drugs appear relatively safe, however, only griseofulvin has a long track record of safety, is Food and Drug Administration (FDA) approved for the treatment of tinea capitis in children, and has the least known drug interactions. Fluconazole is FDA approved for use in children more than 6 months of age, yet not for the treatment of tinea capitis. Oral griseofulvin and terbinafine tablets are the least expensive of the antifungal agents; griseofulvin suspension is, however, more expensive than fluconazole suspension. For the combined reasons of efficacy, safety, and cost, and a long track record of use, we feel oral griseofulvin is still the present treatment of choice for tinea capitis. Newer antifungals are currently under investigation, and their role in treating tinea capitis in children is still being defined.
     </abstracttext>
    </abstract>
    <affiliation>
     Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Bennett
      </lastname>
      <forename>
       M L
      </forename>
      <initials>
       ML
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fleischer
      </lastname>
      <forename>
       A B
      </forename>
      <initials>
       AB
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Loveless
      </lastname>
      <forename>
       J W
      </forename>
      <initials>
       JW
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Feldman
      </lastname>
      <forename>
       S R
      </forename>
      <initials>
       SR
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
     <publicationtype>
      Review
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     UNITED STATES
    </country>
    <medlineta>
     Pediatr Dermatol
    </medlineta>
    <nlmuniqueid>
     8406799
    </nlmuniqueid>
    <issnlinking>
     0736-8046
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Antifungal Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      126-07-8
     </registrynumber>
     <nameofsubstance>
      Griseofulvin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Pediatr Dermatol. 2000 Jul-Aug;17(4):325-6
     </refsource>
     <pmid version="1">
      10990588
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Oral
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Antifungal Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      economics
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Child, Preschool
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clinical Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Griseofulvin
     </descriptorname>
     <qualifiername majortopicyn="N">
      economics
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tinea Capitis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      microbiology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Trichophyton
     </descriptorname>
     <qualifiername majortopicyn="N">
      drug effects
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <numberofreferences>
    34
   </numberofreferences>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2000
     </year>
     <month>
      9
     </month>
     <day>
      16
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2000
     </year>
     <month>
      10
     </month>
     <day>
      7
     </day>
     <hour>
      11
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2000
     </year>
     <month>
      9
     </month>
     <day>
      16
     </day>
     <hour>
      11
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     10990583
    </articleid>
    <articleid idtype="pii">
     pde1784
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

